Cancer Diagnosis Begins Before the Referral
A woman notices a persistent bloating that has not eased over several weeks. She considers it, decides it is probably nothing, and thinks about how full the surgery's phone lines are at eight in the morning. She does not ring. Nothing in the NHS's cancer performance data records this moment, yet it may shape her outcome more than anything that happens after she is eventually referred.
Work led by Dr Elizabeth Towers in Essex puts numbers on that hesitation. Local research found that around 70 per cent of residents would be worried by symptoms of ovarian cancer, while only about 40 per cent would book a GP appointment, many fearing they were wasting the doctor's time. A thirty-point gap between concern and action is not an information deficit in the usual sense. People know something is wrong. They are weighing the cost of seeking help against a system they believe is too stretched to want them.
That belief is not irrational, and this is where the Essex material becomes relevant beyond one integrated care system. Cancer policy has been dominated for years by the supply side: the 28-day faster diagnosis standard, the 62-day treatment pathway, diagnostic capacity, community diagnostic centres. These matter, and the 62-day standard has stubbornly missed its target. But every one of those clocks starts after the patient has already decided to come forward. The interval before that decision is largely unmanaged, unreported and, in many places, unfunded.
The Essex response is deliberately modest in form. Microgrants allowed local organisations to hold conversations about breast screening in places people already trust, with Urdu translation, tactile materials for visually impaired women and peer support. Breast Screening Champions emerged from those sessions, and a film reached more than 15,000 views. For cervical screening, surveys identified anxiety, embarrassment and practical obstacles, and the answer was short films in which a local GP explained what an appointment involves and what adjustments are available. Prostate work will focus on Black men over 45 and men with a family history. A bowel cancer survey, open until early December, will direct where the next round of money goes in 2027.
None of this is expensive, and that is both its appeal and its weakness. The method treats the barriers as local and specific, which they are. Embarrassment about a smear test and fear of wasting a GP's time are different problems requiring different messages from different voices. National campaigns tend to flatten that. Community-based design does not, and it is consistent with the direction of the government's ambition to move care closer to neighbourhoods and to tackle inequalities in outcomes rather than average performance.
Two difficulties need stating plainly. The first is capacity. If community work succeeds in turning the 40 per cent into something closer to 70, primary care and diagnostics will see more patients, many of whom will have benign conditions. General practice is already carrying workload that its workforce cannot comfortably meet, and diagnostic services have only recently begun to approach their own targets. Encouraging earlier help-seeking without a credible plan for the downstream activity risks producing frustration rather than earlier stage diagnosis, and the patients most likely to be discouraged are the ones the programmes aim to reach. Leaders in other systems considering similar work should model the demand before they promote it.
The second difficulty is evidence. A film viewed 15,000 times is an output. It tells us that people watched, not that anyone booked an appointment, attended screening or was diagnosed at an earlier stage. Population-level change in cancer stage is slow to appear and hard to attribute, which makes small community programmes easy to defend with anecdote and easy to cut when budgets tighten. They are also arriving at a vulnerable moment. Integrated care boards have been told to reduce running costs sharply, and prevention and engagement budgets are the kind that give way first because their returns accrue to someone else's accounts and someone else's electoral cycle. A system that asks local teams to reduce inequalities while shrinking the teams is asking for a result it has not resourced.
There is a practical way through. Commissioners could treat community engagement as part of the pathway rather than a communications function, with measurable intermediate indicators: screening uptake in named communities, symptomatic referral rates by practice, and stage at diagnosis tracked over several years. Microgrants could be paired with an agreement from primary care networks about how additional demand will be handled. Industry and health-tech firms working on risk stratification and digital symptom checkers should note that the barrier these Essex surveys identify is emotional and social, and that software which ignores it will struggle to change behaviour.
Earlier diagnosis is one of the few areas of health policy where the clinical, financial and political arguments point the same way. Cancers found sooner are cheaper to treat and more often curable. The Essex programme suggests where some of the lost time sits. Whether the NHS will pay attention to a part of the pathway it does not currently count is a harder question, and the answer will show in the staging data well before it appears in a strategy document.
